Modus Therapeutics AB
Swedish biotech developing sevuparin for severe inflammatory diseases.
Oversikt
- Ukjent
- Ansatte
- Ukjent
- Omsetning
- 2004
- Grunnlagt
Nøkkelbeslutningstakere
John Öhd
Chief Executive Officer
Johan Dighed
Board member
Viktor Drvota
Chairman
Michael Forer
Member of the Nomination Committee
+3 flere kontakter i Funnelfeedr
Beskrivelse
Modus Therapeutics is a Swedish biotechnology company focused on developing novel treatments for severe medical conditions with high unmet needs. Their proprietary polysaccharide, sevuparin, is the core asset under development. Sevuparin is designed as a heparinoid that modifies inflammation while m...